GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Translational Development Acquisition TDAC · USD

N/A · US listing · 🇺🇸 United States

Compare

10.87

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Translational Development Acquisition

From its filings with the US Securities and Exchange Commission

SEC filings

Translational Development Acquisition is based in New York, New York. Its shares trade on Nasdaq under the ticker TDAC. The SEC classifies its business as blank checks. In the fiscal year to 31 December 2025, it reported net income of $6.4m. At that date it held total assets of $181.7m and shareholders' equity of −$6.5m.

In its own words

The registration statement (File No. 333-282763) (the “Registration Statement”) for our initial public offering was declared effective on December 20, 2024 (the “IPO”). On December 24, 2024, we consummated the IPO of 17,250,000 units (the “Units”), which includes the full exercise of the underwriter’s over-allotment option. Each Unit consists of one Class A ordinary share (the “Ordinary Share”) and one-half of one redeemable warrant (the “Warrant”), each whole Warrant entitling the holder thereof to purchase one Ordinary Share for $11.50 per share. The Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $172,500,000.

Simultaneously with the closing of the IPO, we consummated the private placement (“Private Placement”) with TDAC Partners LLC (the “Sponsor”) and BTIG LLC (the “Underwriter”), an aggregate of 7,075,000 (the “Private Placement Warrants”) at a price of $1.00 per warrant, generating total proceeds of $7,075,000. Of those 7,075,000 Private Placement Warrants, the Sponsor purchased 4,850,000 Private Placement Warrants and the Underwriter purchased 2,225,000 Private Placement Warrants. The Private Placement Warrants (and underlying securities) are identical to the Warrants included in the Units sold in the IPO, except as otherwise disclosed in the Registration Statement. No underwriting discounts or commissions were paid with respect to such sale. The issuance of the Private Placement Warrants was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗

Company facts

Sector
N/A
Industry
N/A
Listed since
23 Dec 2024
Head office
52 E 83RD ST., NEW YORK, NY, 10028
Classification
Blank Checks
Filer status
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Michael HoffmanChairman of the Board, Chief Executive Officer, since 2022
  • Mr. Avanindra DasChief Financial Officer
  • Mr. Christopher JarrattIndependent Director
  • Dr. Curtis KeithIndependent Director
  • Mr. Matthew KestenbaumIndependent Director
  • Dr. E. Premkumar ReddyIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company is a blank check firm formed for business combinations.
  • Translational Development Acquisition Corp targets one or more businesses for merger.
  • The firm was formed for asset acquisition or share purchase deals.

Weaknesses

  • The firm has not selected any specific business combination target yet.
  • The company has neither engaged in any operations nor generated revenues.
  • Translational Development Acquisition Corp has not engaged in substantive discussions with targets.

Opportunities

  • The company aims to effect a merger with one or more businesses.
  • Translational Development Acquisition Corp seeks share exchange or reorganization opportunities.
  • The firm plans asset acquisition or similar business combination structures.

Threats

  • The company has not engaged in substantive discussions with any target.
  • Translational Development Acquisition Corp has not generated any revenues to date.
  • The firm has not selected a specific business combination target.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.